Last reviewed: July 9, 2026
Last updated: July 9, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Tirzepatide, the active ingredient in Zepbound, produced average weight loss of 20-22% of baseline body weight in the SURMOUNT trials, making it one of the most studied GLP-1 receptor agonists for obesity management. Real-world outcomes vary significantly based on individual metabolic factors, adherence to dosing schedules, and dietary habits. Understanding what weight loss to expect helps you set realistic goals and track progress with your PlexusDx provider.
Clinical Trial Weight Loss Results with Tirzepatide
The SURMOUNT-1 trial demonstrated that participants receiving tirzepatide 15 mg weekly lost an average of 22.5% of their starting body weight over 68 weeks, compared to 2.4% in the placebo group. Participants on the highest approved dose (15 mg) achieved the most substantial reductions, though meaningful weight loss began at lower doses. These results represent one of the highest efficacy rates among injectable weight loss medications currently available in the United States.
Weight loss typically becomes noticeable within 4-8 weeks of consistent dosing, with the most significant reductions occurring between weeks 8 and 24. The trajectory continues steadily through 52 weeks of treatment, after which weight stabilizes for most users. Individual variation is substantial—some patients lose 15% of body weight while others achieve 30% or more, depending on genetics, metabolism, and lifestyle factors.
Factors That Influence Your Personal Weight Loss Outcome
Your genetic makeup affects how your body responds to tirzepatide through peptide-pathway variations that influence appetite signaling, insulin sensitivity, and energy expenditure. The PlexusDx Precision Peptide Genetic Test identifies key variants in GLP1R, GIPR, FTO, and MC4R genes—markers that correlate with weight loss response patterns in clinical populations. Knowing your genetic profile allows your PlexusDx provider to customize your starting dose and escalation schedule for optimal results.
Beyond genetics, consistent adherence to weekly injections produces better outcomes than missed or delayed doses, since tirzepatide's appetite-suppressing effects depend on maintaining steady medication levels. Dietary quality matters significantly—users who reduce processed foods and increase protein intake typically experience faster, more stable weight loss. Exercise intensity is less critical for initial weight loss but becomes increasingly important for maintaining results after you discontinue the medication.
Tirzepatide Dose Levels and Weight Loss Expectations
Tirzepatide treatment typically starts at 2.5 mg weekly, a dose chosen to minimize gastrointestinal side effects while allowing your body to adapt to the medication's appetite-suppressing mechanism. After 4 weeks, your dose increases to 5 mg, then progresses through 7.5 mg, 10 mg, 12.5 mg, and finally 15 mg at 4-week intervals, assuming you tolerate each level well. Your dose may need to go up based on your response and tolerance, but your price remains flat—PlexusDx charges one monthly rate regardless of which dose you're using.
Lower doses (2.5-7.5 mg) typically produce 10-15% weight loss over several months, sufficient for many patients to reach their goals. Higher maintenance doses (10-15 mg) generally yield 18-25% weight loss, though individual results still vary considerably. Some patients achieve their target weight at 10 mg and choose to stay there, while others continue to 15 mg for maximum effect. Your PlexusDx provider reviews your progress monthly and adjusts your dose strategy based on actual outcomes, not assumptions.
How Tirzepatide Works Differently Than GLP-1 Only Medications
Tirzepatide activates both GLP-1 and GIP receptors in your brain and digestive system, creating a dual-pathway effect on appetite, satiety, and metabolic rate that single-pathway medications cannot replicate. This dual action explains why tirzepatide users in clinical trials lost more weight than semaglutide users in comparable studies—the additional GIP signaling amplifies appetite suppression and enhances insulin secretion. PlexusDx offers both tirzepatide and semaglutide injections, allowing your provider to match the mechanism of action to your individual needs and genetic predispositions.
The PlexusDx Precision Peptide Genetic Test analyzes GIPR — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
Maintaining Weight Loss After You Stop Tirzepatide
Weight regain typically begins within weeks after discontinuing tirzepatide because the appetite-suppressing signals fade as the medication leaves your system. Clinical follow-up data shows that patients who maintain dietary changes and exercise habits regain approximately 50-75% of their lost weight within one year, though some maintain more substantial portions of their initial loss. This pattern reflects the chronic nature of obesity—the body's appetite regulation pathways are essentially rewired over time, and medication addresses the biology rather than curing it permanently.
Long-term treatment continuation is the most reliable strategy for sustaining weight loss, which is why many patients remain on tirzepatide indefinitely or cycle through seasonal treatment phases. Some PlexusDx patients pause treatment temporarily to assess whether behavioral changes alone maintain progress, then resume if weight begins climbing back. Your provider can help you develop a personalized maintenance plan that balances cost, convenience, and your individual metabolic needs for sustainable long-term weight management.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the average weight loss with Zepbound in the first month?
Most users don't notice significant weight loss in the first 4 weeks because the starting dose (2.5 mg) is intentionally low to allow tolerance. Weight loss acceleration typically begins in weeks 4-8 as your dose increases to 5 mg and your body adapts to the appetite-suppressing effects. By 8-12 weeks, average weight loss ranges from 5-10 pounds depending on your starting weight and dietary adherence.
Can I expect to lose 20% of my body weight like the clinical trials showed?
No — the Precision Peptide Genetic Test does not predict your response to Zepbound or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
How does PlexusDx tirzepatide pricing work for different dose levels?
PlexusDx charges a flat monthly rate for compounded tirzepatide starting at $289/month across all commitment tiers—your dose may need to go up, but your price won't change. Whether you're taking 2.5 mg or 15 mg weekly, you pay the same monthly fee, making it economical to reach your optimal effective dose without worrying about price escalation.
Is compounded tirzepatide from PlexusDx as effective as brand-name Zepbound?
PlexusDx tirzepatide comes from licensed 503A compounding pharmacies that manufacture identical active pharmaceutical ingredients under strict quality standards. The weight loss outcomes depend on the tirzepatide molecule itself, not whether it's compounded or brand-name, so efficacy is equivalent. Compounding allows PlexusDx to serve all 50 states without insurance requirements and at lower cost than brand-name options.
How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?
The PlexusDx Precision Peptide Genetic Test identifies variants in GLP1R, GIPR, FTO, and MC4R that influence your metabolic predispositions and likely medication response—it doesn't predict an exact number, but it reveals whether your genetics favor strong tirzepatide responsiveness, slower initial weight loss, or enhanced insulin sensitivity. Combined with your starting weight, age, and lifestyle data, these genetic insights allow your provider to forecast a realistic range for your 3-month and 6-month outcomes.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How Many Wegovy Pens Per Month? Understanding Your Dosage Needs
Starting Strong: Can I Start at a Higher Dose of Wegovy for Weight Loss?